The stock of Diplomat Pharmacy Inc (NYSE:DPLO) reached all time low today, Nov, 3 and still has $12.35 target or 5.00% below today’s $13.00 share price. This indicates more downside for the $855.27M company. This technical setup was reported by Barchart.com. If the $12.35 PT is reached, the company will be worth $42.76M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 15.61M shares traded hands or 1599.02% up from the average. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 23.51% since April 1, 2016 and is downtrending. It has underperformed by 24.73% the S&P500.
Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage
Out of 8 analysts covering Diplomat Pharmacy (NYSE:DPLO), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. $55 is the highest target while $17 is the lowest. The $34.83 average target is 167.92% above today’s ($13) stock price. Diplomat Pharmacy has been the topic of 12 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by Bank of America given on Wednesday, October 14. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Buy” rating by UBS on Wednesday, October 21. On Wednesday, October 21 the stock rating was maintained by Mizuho with “Buy”. Leerink Swann maintained the shares of DPLO in a report on Tuesday, August 4 with “Outperform” rating. Morgan Stanley downgraded it to “Equal-Weight” rating and $31 target price in Friday, October 2 report. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Neutral” rating by Mizuho on Thursday, November 3. The stock has “Overweight” rating given by Barclays Capital on Wednesday, January 6. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Neutral” rating by Bank of America on Tuesday, June 7. The firm has “Market Perform” rating by Cowen & Co given on Friday, June 24. On Wednesday, May 11 the stock rating was maintained by Mizuho with “Neutral”.
According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”
Insitutional Activity: The institutional sentiment decreased to 1.43 in 2016 Q2. Its down 0.22, from 1.65 in 2016Q1. The ratio dived, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.
Alliancebernstein L P last reported 0.07% of its portfolio in the stock. The New York-based Goldman Sachs Grp Inc Inc has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Independent Portfolio Consultants Inc owns 21,705 shares or 0.24% of their US portfolio. Wealthtrust reported 130 shares or 0% of all its holdings. California Employees Retirement, a California-based fund reported 19,600 shares. Legal General Grp Public Limited Com reported 8,983 shares or 0% of all its holdings. Great West Life Assurance Can last reported 0% of its portfolio in the stock. First Trust Limited Partnership has 24,398 shares for 0% of their US portfolio. Raymond James And Assoc holds 0% or 31,352 shares in its portfolio. Springbok Cap Management Lc, a New York-based fund reported 2,627 shares. Fmr Ltd Co accumulated 0.01% or 1.12M shares. State Of Tennessee Treasury Department accumulated 28,220 shares or 0.01% of the stock. Tiaa Cref Inv Mgmt Limited Co has 190,955 shares for 0.01% of their US portfolio. Moreover, Assetmark Incorporated has 0% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 885 shares. The Arizona-based Arizona State Retirement Systems has invested 0.01% in Diplomat Pharmacy Inc (NYSE:DPLO).
Insider Transactions: Since August 1, 2016, the stock had 0 insider buys, and 2 selling transactions for $1.04 million net activity. $440,794 worth of Diplomat Pharmacy Inc (NYSE:DPLO) was sold by Kaddis Atheer A on Monday, August 1.
More recent Diplomat Pharmacy Inc (NYSE:DPLO) news were published by: Fool.com which released: “Why Diplomat Pharmacy, Inc. Is Plunging Today” on November 03, 2016. Also Fool.com published the news titled: “Why Diplomat Pharmacy, Inc. Shares Are Falling 13.6% Today” on October 26, 2016. Schaeffersresearch.com‘s news article titled: “Buzz Stocks: Chesapeake Energy Corporation, Diplomat Pharmacy Inc, and Wells …” with publication date: November 03, 2016 was also an interesting one.
DPLO Company Profile
Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.